AIROS Medical launches FDA-cleared home compression device for peripheral arterial disease
Published: 16 Mar 2026
Author: Precedence Research
AIROS Medical, Inc. is a medical technology manufacturer that specialises in compression therapy systems and has the launch of the U.S. Food and Drug Administration 510(k)-cleared ARTAIRA designed device that increases blood flow and circulation to the lower extremities to treat patients with symptoms of peripheral arterial disease. The American Limb Preservation Society
PAD is a serious vascular condition where narrowed arteries reduce blood flow to the limbs, usually the legs, causing painful symptoms, tissue death, and infections. The ARTAIRA device delivers high-pressure compression cycles to the ankle and foot to increase blood flow to the legs, feet, and toes. Chief Operating Officer of AIROS Medical, Inc., Darren M. Behuniak says ARTAIRA increases circulation to treat these conditions and help patients return to regular activities and lifestyles.
The company has focused on treating patients with lymphedema and chronic venous insufficiency, and thrilled to apply our user-friendly pneumatic compression technology to this adjacent patient population with vascular disorders.
According to Toward Healthcare, the Sequential Compression System Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.41 billion in 2026 to approximately USD 2.9 billion by 2035, representing a compound annual growth rate (CAGR) of 8.37% from 2026 to 2035. The ARTAIRA device is a promising non-invasive solution to improve PAD management, particularly for home-based care, though its long-term impact will depend on patient adherence and healthcare integration.
Bringing Advanced Compression Therapy Home
The newly launched ARTAIRA device is designed specifically to increase blood flow and circulation in the lower extremities. The company has given a user-friendly interface. As health care systems continue to push care into lower-cost settings, accessibility is a crucial factor while ensuring patients who need it most can obtain this innovative tool without facing overwhelming with financial burdens.
ARTAIRA is now available throughout the United States and is reimbursed by Medicare and commercial health insurers with proper documentation. AIROS Medical will support the launch through clinical education programs, professional workshops, and live demonstrations at podiatric, vascular, and wound care conferences.
A recent report by Toward Healthcare highlights that the Sequential Compression System Market is experiencing healthcare providers adopting the device's clinical applications and benefits, paving the way for its adoption as a new tool in the fight against the debilitating effects of Peripheral Arterial Disease.